Article
Immunology
Elizabeth S. Aby, Byron P. Vaughn, Eva A. Enns, Radha Rajasingham
Summary: This study assessed the cost-effectiveness of fecal microbiota transplantation (FMT) for first recurrent Clostridioides difficile infection (CDI). The findings indicate that FMT is a cost-effective treatment strategy for first recurrent CDI.
CLINICAL INFECTIOUS DISEASES
(2022)
Review
Gastroenterology & Hepatology
Paul Feuerstadt, Olga C. Aroniadis, Felicia L. Svedlund, Mariana Garcia, Laura Stong, Mena Boules, Sahil Khanna
Summary: There is significant heterogeneity in methods and reporting among randomized controlled trials (RCTs) of FMT for recurrent Clostridioides difficile infection (rCDI). Variability exists in FMT preparations, sample sizes, control groups, and adverse event follow-up periods. Lack of standardized care control may impact reproducibility of FMT trial outcomes in patients with rCDI.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Multidisciplinary Sciences
Olle Bjorkqvist, Ignacio Rangel, Lena Serrander, Cecilia Magnusson, Jonas Halfvarson, Torbjorn Noren, Malin Bergman-Jungestrom
Summary: The study found that FMT can increase the relative abundance of Faecalibacterium prausnitzii in patients with recurrent CDI, and this microbial shift persists for several months later. Further research is needed to determine whether Faecalibacterium prausnitzii actively contributes to the resolution of CDI.
Review
Microbiology
R. E. Ooijevaar, E. van Nood, A. Goorhuis, E. M. Terveer, J. van Prehn, H. W. Verspaget, Y. H. van Beurden, M. G. W. Dijkgraaf, J. J. Keller
Summary: Research suggests that in patients with recurrent Clostridioides difficile infection, long-term follow-up after fecal microbiota transplantation (FMT) does not show new adverse health issues, and no deaths directly attributable to FMT were identified.
Article
Immunology
Jie Wu, Liang Lv, Chunlian Wang
Summary: The meta-analysis examined the efficacy of fecal microbiota transplantation (FMT) in irritable bowel syndrome (IBS) and found inconsistent results. FMT administered via colonoscopy or gastroscope may benefit IBS patients and improve their quality of life. However, the quality of evidence supporting the use of FMT in IBS is very low.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Gastroenterology & Hepatology
Raseen Tariq, Darrell S. S. Pardi, Sahil Khanna
Summary: Microbiota restoration shows higher efficacy in observational studies compared to randomized controlled trials (RCTs) for treating recurrent Clostridioides difficile infection (CDI), likely due to stricter definitions and inclusion criteria in RCTs. The results from observational studies and open-label trials are similar.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Azizullah Beran, Sachit Sharma, Sami Ghazaleh, Wade Lee-Smith, Muhammad Aziz, Faisal Kamal, Ashu Acharya, Douglas G. Adler
Summary: This meta-analysis explored the predictors of fecal microbiota transplantation (FMT) failure in patients with recurrent/refractory Clostridioides difficile infection (CDI). The study included 20 studies with a total of 4327 patients and found that FMT failed in 16.3% of the patients. Advanced age, severe CDI, inflammatory bowel disease, peri-FMT use of non-CDI antibiotics, prior CDI-related hospitalizations, inpatient status, and poor quality of bowel preparation were significant predictors of FMT failure.
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Shaodong Wei, Martin Iain Bahl, Simon Mark Dahl Baunwall, Jens Frederik Dahlerup, Christian Lodberg Hvas, Tine Rask Licht
Summary: This study aimed to explore the relationship between early changes in the intestinal microbiota and clinical outcomes following fecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection (CDI). The results showed that patients with sustained resolution after FMT had different microbial diversity, abundance, and gut microbiota dysbiosis compared to non-responders. Additionally, a constructed index based on clinically feasible methods successfully predicted treatment failure. It was also found that FMT had a more pronounced impact on the gut microbiota compared to antibiotic monotherapy. Therefore, early identification of microbial community structures after FMT is clinically valuable for predicting treatment response.
Letter
Medicine, General & Internal
Nicolas Benech, Tatiana Galperine, Harry Sokol
Summary: This article compares the efficacy of SER-109 and fecal microbiota transplantation (FMT) in preventing recurrent Clostridioides difficile infection. The recurrence rate was lower than expected in the placebo group, while FMT showed benefits in preventing recurrent C. difficile infection among patients with a history of multiple cases.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Maribeth R. Nicholson, Suchitra K. Hourigan, Maire Conrad, Alka Goyal, Kyle Jensen, Judith Kelsen, Melissa Kennedy, Madison Weatherly, Stacy A. Kahn
Summary: The impact of the 2019 US FDA safety alert and the COVID-19 pandemic on the use of FMT in children has led to changes in practices for many pediatric gastroenterologists, with a majority of programs being halted as a result.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Gastroenterology & Hepatology
Anna Maria Seekatz, Nasia Safdar, Sahil Khanna
Summary: The composition of the human gut microbiota is important for overall health, and disruptions in this microbiome can lead to various diseases. In the case of Clostridioides difficile infection, standard treatments and monoclonal antibodies do not address the underlying dysbiosis. Fecal microbiota transplantation (FMT) is an effective strategy in preventing recurrent infections, but there are challenges in screening and standardizing the acquisition and processing of donor stool. Newer biotherapeutic formulations are being developed to improve gut microbiome restoration and prevent CDI recurrence.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2022)
Review
Immunology
Yapeng Li, Tingting Zhang, Jiahui Sun, Nanyang Liu
Summary: This study conducted an umbrella review to summarize the evidence of the association between fecal microbiota transplantation (FMT) and health outcomes. The findings suggest potential benefits of FMT for antibiotic resistance burden, functional constipation, inflammatory bowel disease, and C. difficile infection. However, caution should be exercised in choosing this approach due to the insufficient number of primary studies, low methodological quality, and low quality of evidence.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Gastroenterology & Hepatology
Tanveer Singh, Prabhjot Bedi, Karandeep Bumrah, Darshan Gandhi, Tanureet Arora, Nikita Verma, Mary Schleicher, Manoj P. Rai, Rajat Garg, Beni Verma, Madhusudhan R. Sanaka
Summary: Fecal microbiota transplantation (FMT) is effective in the treatment of recurrent Clostridium difficile infection (CDI), but not significant in primary CDI.
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2022)
Article
Oncology
Hiba Ali, Shruti Khurana, Weijie Ma, Yuanzun Peng, Zhi-Dong Jiang, Herbert DuPont, Hao Chi Zhang, Anusha S. Thomas, Pablo Okhuysen, Yinghong Wang
Summary: Patients with cancer who underwent FMT for rCDI showed a high response rate and no serious adverse events or mortality within 30 days. However, additional antibiotic use for complications from chemotherapy or immunosuppression may negatively affect the efficacy of FMT in this population with advanced cancer.
Review
Infectious Diseases
Raseen Tariq, Maham Hayat, Darrell Pardi, Sahil Khanna
Summary: Fecal microbiota transplantation (FMT) is an effective therapy for CDI, but has a failure rate of around 15%. Factors such as use of non-CDI antibiotics, presence of inflammatory bowel disease, poor bowel preparation, CDI-related hospitalization before FMT, inpatient FMT, and severe CDI are associated with increased risk of FMT failure. Modifiable factors like antibiotic use post-FMT and good bowel preparation can lower the risk of failure. Patients with non-modifiable risk factors should be more vigilant for recurrent symptoms after FMT.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2021)